MARKET

ADPT

ADPT

Adaptive Biotechnologies
NASDAQ

Real-time Quotes | Nasdaq Last Sale

45.82
-2.39
-4.96%
After Hours: 45.82 0 0.00% 16:50 09/24 EDT
OPEN
47.58
PREV CLOSE
48.21
HIGH
48.84
LOW
45.71
VOLUME
1.46M
TURNOVER
--
52 WEEK HIGH
49.00
52 WEEK LOW
15.19
MARKET CAP
6.22B
P/E (TTM)
-58.0662
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Lilly and Amgen partner to manufacture potential coronavirus drugs
Eli Lilly has partnered with Amgen to increase the capacity of its experimental C-19 antibody treatment, a day after one of the drug was shown to reduce the need for hospitalization.
Reuters · 09/17 11:17
Adaptive Biotechnologies to Present at the Morgan Stanley 2020 Healthcare Conference
SEATTLE, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in
GlobeNewswire · 09/01 21:03
Adaptive Biotechnologies: T-Cell Explorer In COVID-19 Battle Deserves A Premium
The upside from Adaptive’s recent FDA approval pales into insignificance compared to potential returns from its COVD-19 ventures.
Seeking Alpha - Article · 08/14 18:57
Personalis Turns to Liquid Biopsies for Growth. Will It Work?
MotleyFool.com - Paid Partner Content · 08/14 13:33
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 13.33% and 3.64%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/10 22:35
Adaptive Biotechnologies Reports Second Quarter 2020 Financial Results
SEATTLE, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to di
GlobeNewswire · 08/10 20:05
Did Hedge Funds Make The Right Call On Adaptive Biotechnologies Corporation (ADPT)?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter
Insider Monkey · 08/10 16:44
Adaptive Biotechnologies to Present at the UBS Genomics 2.0 and Medtech Innovations Summit
SEATTLE, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, tod
GlobeNewswire · 08/10 12:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADPT. Analyze the recent business situations of Adaptive Biotechnologies through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADPT stock price target is 51.80 with a high estimate of 63.00 and a low estimate of 42.00.
EPS
Institutional Holdings
Institutions: 254
Institutional Holdings: 101.43M
% Owned: 74.70%
Shares Outstanding: 135.79M
TypeInstitutionsShares
Increased
62
8.64M
New
75
2.55M
Decreased
50
7.08M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
-0.82%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Executive Director
Chad Robins
President
Julie Rubinstein
Co-Founder/Chief Scientific Officer
Harlan Robins
Chief Financial Officer
Chad Cohen
Senior Vice President/General Manager
.. Willis
Chief Human Resource Officer
Francis Lo
Senior Vice President/General Counsel
Stacy Taylor
Senior Vice President
Sharon Benzeno
Senior Vice President
Nancy Hill
Senior Vice President
Jyoti Palaniappan
Senior Vice President
Charles Snag
Chief Technology Officer
Mark Adams
Other
Lance Baldo
Other
Sean Nolan
Lead Director/Independent Director
Peter Neupert
Independent Director
Kevin Conroy
Independent Director
Eric Dobmeier
Independent Director
David Goel
Independent Director
Michelle Griffin
Independent Director
Robert Hershberg
Independent Director
Michael Pellini
Independent Director
Andris Zoltners
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ADPT
Adaptive Biotechnologies Corp is a biotechnology company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. It offers its immunoSEQ technology as a service and a kit. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). clonoSEQ is its diagnostic test product for the detection and next-generation sequencing (NGS)-based monitoring of minimal residual disease (MRD) in bone marrow samples in patients with myeloma (MM) and acute lymphoblastic leukemia (ALL). clonoSEQ is designed to sequence all rearranged receptor sequences in a tumor in parallel to enable MRD monitoring. It also focuses on developing immune-mediated therapies in oncology and other disease areas.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Adaptive Biotechnologies Corp stock information, including NASDAQ:ADPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADPT stock methods without spending real money on the virtual paper trading platform.